AOLS (Aeolus Pharmaceuticals) Retained Earnings: $-193.26 Mil (As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aeolus Pharmaceuticals Retained Earnings?

Aeolus Pharmaceuticals AOLS Retained Earnings is $-193.26 Mil as of Jun. 2017.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Aeolus Pharmaceuticals's retained earnings for the quarter that ended in Jun. 2017 was $-193.26 Mil.

Aeolus Pharmaceuticals's quarterly retained earnings declined from Dec. 2016 ($-191.28 Mil) to Mar. 2017 ($-192.31 Mil) and declined from Mar. 2017 ($-192.31 Mil) to Jun. 2017 ($-193.26 Mil).

Aeolus Pharmaceuticals's annual retained earnings declined from Sep. 2014 ($-184.00 Mil) to Sep. 2015 ($-186.63 Mil) and declined from Sep. 2015 ($-186.63 Mil) to Sep. 2016 ($-190.19 Mil).


Aeolus Pharmaceuticals  (OTCPK:AOLS) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Aeolus Pharmaceuticals Retained Earnings Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals Retained Earnings Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -180.71 -183.92 -184.00 -186.63 -190.19

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -189.17 -190.19 -191.28 -192.31 -193.26

Aeolus Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-193.26 Mil mean?
Aeolus Pharmaceuticals (AOLS) has a Retained Earnings of $-193.26 Mil as of Jun. 2017. Retained earnings is the amount of net income not issued to shareholders. View historical data on Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' Retained Earnings too high?
Aeolus Pharmaceuticals' current Retained Earnings is $-193.26 Mil.
How does Aeolus Pharmaceuticals' Retained Earnings compare to RDGL and PCYN?
Aeolus Pharmaceuticals' Retained Earnings of $-193.26 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Aeolus Pharmaceuticals and its competitors. Aeolus Pharmaceuticals's current Retained Earnings is $-193.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current Retained Earnings of $-193.26 Mil. The current Retained Earnings is $-193.26 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current Retained Earnings is $-193.26 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.